Treatment-related leukopenia in anal cancer patients associated with worse outcome: results of a retrospective cohort study

References

• Deshmukh AA, Suk R, Shiels MS, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015. J Natl Cancer Inst. 2019;112:829–838.
   Google Scholar
• Guren MG, Aagnes B, Nygard M, et al. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987–2016. Clin Colorectal Cancer. 2019;18(1):e96–e103.
   PubMed Web of Science ®Google Scholar
• Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2013;119(4):748–755.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87(4):638–645.
   PubMed Web of Science ®Google Scholar
• Shakir R, Adams R, Cooper R, et al. Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;106(2):329–339.
   PubMed Web of Science ®Google Scholar
• Leon O, Guren M, Hagberg O, et al. Anal carcinoma - survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol. 2014;113(3):352–358.
   PubMed Web of Science ®Google Scholar
• Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Critic Rev Oncol Hematol. 2018;123:42–51.
   PubMed Web of Science ®Google Scholar
• Hamilton SN, Urban R, Liu A, et al. Population-based outcomes by immunosuppressed status in patients undergoing radiotherapy for oropharyngeal cancer. Radiother Oncol. 2020;151:110–117.
   PubMed Web of Science ®Google Scholar
• Martin D, Rodel F, Winkelmann R, et al. Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer. Front Immunol. 2017;8:1225.
   PubMed Web of Science ®Google Scholar
• Schernberg A, Huguet F, Moureau-Zabotto L, et al. External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation. Radiother Oncol. 2017;124(1):110–117.
   PubMed Web of Science ®Google Scholar
• Martin D, Rödel F, von der Grün J, et al. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol. 2020;149:168–173.
   PubMed Web of Science ®Google Scholar
• Lee G, Kim DW, Muralidhar V, et al. Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal. Oncologist. 2020. DOI:10.1634/theoncologist.2019-0759
   Web of Science ®Google Scholar
• Nilsson MP, Nilsson ED, Johnsson A, et al. Patterns of recurrence in anal cancer: a detailed analysis. Radiat Oncol. 2020;15(1):125.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Bingmer K, Ofshteyn A, Dietz DW, et al. Outcomes in immunosuppressed anal cancer patients. Am J Surg. 2020;219(1):88–92.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Meadows HM, Lopes A, et al. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Ann Oncol. 2020;31(10):1376–1385.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–835.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ellsworth S, Campian J, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015;13(10):1225–1231.
   PubMed Web of Science ®Google Scholar
• Wu ES, Oduyebo T, Cobb LP, et al. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;140(1):76–82.
   PubMed Web of Science ®Google Scholar
• Thor M, Montovano M, Hotca A, et al. Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression? Radiother Oncol. 2020;143:51–57.
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Serup-Hansen E, Linnemann D, et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. 2016;114(2):134–137.
   PubMed Web of Science ®Google Scholar
• Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19(8):1094–1106.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Leon O, Gunnlaugsson A, et al. Determinants for local tumour control probability after radiotherapy of anal cancer. Radiother Oncol. 2018;128(2):380–386.
   PubMed Web of Science ®Google Scholar
• Mitra D, Hong TS, Horick N, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017;2(2):110–117.
   PubMedGoogle Scholar
• Muirhead R, Partridge M, Hawkins MA. A tumor control probability model for anal squamous cell carcinoma. Radiother Oncol. 2015;116(2):192–196.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Martin D, Balermpas P, Gollrad J, et al. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: a randomized multicenter phase II trial. Clin Trans Radiat Oncol. 2020;23:43–49.
   PubMed Web of Science ®Google Scholar
• Anand A, Bues M, Rule WG, et al. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiother Oncol. 2015;117(3):505–508.
   PubMed Web of Science ®Google Scholar